Perphenazine Market Size, Share, Growth, and Industry Analysis, By Type (Oral Forms and Injectable Solution), By Application (Psychosis and Antiemetic), Regional Insights, and Forecast To 2034

• 

  Request a Free sample to learn more about this report

PERPHENAZINE MARKET OVERVIEW

The global Perphenazine Market is poised for significant growth USD 0.106 billion in 2025, and projected to reach USD 0.118 billion by 2034, with a CAGR of 1.36% from 2025 to 2034.

The United States Perphenazine market size is projected at USD 0.0364 billion in 2025, the Europe market at USD 0.0289 billion, and the China market at USD 0.0264 billion.

The anti-psychotic drug perphenazine belongs to the class of medications known as phenothiazines. It functions by altering the way that certain brain chemicals behave. Schizophrenia and other psychotic diseases are treated with this drug. Extreme nausea and vomiting are also managed with it. Solid or liquid drugs administered by mouth are known as oral forms. They can be given to patients in a number of different forms, including pills, capsules, syrups, and solutions. Sancilio (Phenobar), a chewable tablet containing sodium phenobarbital, is the most widely used oral form of phenobarbital. Parkinson's disease, anxiety disorders, attention deficit hyperactivity disorder (ADHD), epilepsy, multiple sclerosis, rheumatoid arthritis and osteoarthritis pain management, among other illnesses, are treated with perphenazine.

A type of medication delivery device called an injectable solution enables intravenous or subcutaneous administration of medication. The demand for long-acting formulations and the rising prevalence of chronic disorders like diabetes are driving the market for injectable solutions to a profitable growth over the forecast period. Injectable are used to treat a number of conditions, including obesity, osteoporosis, arthritis, and asthma. Based on application, the perphenazine market is divided into psychosis, antiemetic, and other segments. Analgesia, sedation, and general anaesthesia are among the additional applications. Both in terms of income and volume, the antiemetic category dominated the whole market. This high usage rate was mostly brought on by emetophobia—an abnormal dread of vomiting—and nausea brought on by chemotherapy or radiation therapy for cancer.

KEY FINDINGS

COVID-19 Impact: Delays Due to Lockdown to Impede Market Growth

The global COVID-19 pandemic has been unprecedented and staggering, with Perphenazine market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The rise in CAGR is attributed to the perphenazine market growth and demand returning to pre-pandemic levels once the pandemic is over.

It is now difficult to determine whether the present epidemic is a benefit or a curse for the pharmaceutical sector because it has not only wreaked havoc on the country as a whole but also on the whole pharmaceutical industry. As countries and industries continue to cope with the unparalleled challenges presented by the novel coronavirus (COVID-19), a specific area of concern has been the uncertainty surrounding the impact of the COVID-19 pandemic on the global and Indian supply chains of the pharmaceutical industry. The COVID-19 crisis had demonstrated the importance of establishing a risk management system that focuses on assessing future risks resulting from the loss of a supply chain among countries.

The biggest issues identified involved delays, longer lead times, and rising expenses in overseas shipping. Contrary to predictions, manufacturers claimed that their reliance on China for API supplies has decreased in recent years, therefore the shortage of access to the active pharmaceutical ingredients (APIs) needed for ARV drug development was not a significant barrier. The fact that they had to rely on foreign markets for the raw materials needed for domestic API synthesis was a significant obstacle.

LATEST TRENDS

Growing Awareness about Mental Health to Boost Market Growth

The significance of mental health and its effect on general wellbeing are becoming increasingly well-known. The demand for perphenazine will probably rise as a result in the upcoming years. An alarming increase in the prevalence of stress and anxiety has led to a greater demand for this drug and other anxiety and stress management medications. This is the reason why it is provided in therapies.

• According to the World Health Organization (WHO), mental and neurological disorders account for 14% of the global disease burden, significantly increasing demand for antipsychotic drugs like Perphenazine. The WHO's global mental health action plan highlights schizophrenia as one of the priority conditions due to its rising incidence.

• Based on data from the National Institute of Mental Health (NIMH), the U.S. reported that 21 million adults experienced major depressive episodes in 2023, driving pharmaceutical companies to focus more on Perphenazine production for psychiatric treatment.

Request a Free sample to learn more about this report

PERPHENAZINE MARKET SEGMENTATION

• By Type

Based on type; the market is divided into oral forms and injectable solution.

In terms of product, oral forms are the largest segment.

• By Application

Based on application; the market is divided into psychosis and antiemetic.

In terms of application, psychosis is the largest segment.

DRIVING FACTORS

Incidence of Mental Diseases Rising to Enhance Market Growth

The prevalence of mental problems is rising at an alarming rate on a global scale. In the upcoming years, this is anticipated to fuel the need for the drug. The drug helps patients calm down and release tension. It is sold at a large scale in mental asylums and pharmacies. Schizophrenia is a mental condition that causes confused or strange thinking, lack of interest in life, and strong or inappropriate emotions. Perphenazine is used to treat the symptoms of this illness.

• According to CDC Mental Health Statistics, nearly 1 in 25 adults in the U.S. live with a serious mental illness such as schizophrenia, creating sustained demand for Perphenazine in long-term care therapies.

• A recent study published by the National Institutes of Health (NIH) showed a 28% increase in clinical trials involving Perphenazine and related phenothiazines from 2020 to 2024, indicating strong research investment in this molecule's psychiatric applications.

Growing Number of Research Studies on Perphenazine to Augment Market Growth

Perphenazine research has increased significantly in recent years, suggesting possible therapeutic advantages over other drugs for the treatment of mental problems. This is going to encourage perphenazine market growth in the future.

RESTRAINING FACTORS

Inadequate Number of Specialists to Constrain Market Growth

This market's growth is constrained by a number of issues, including the high cost of care and a lack of skilled specialists. Despite increased awareness, few people take mental health seriously. There is a dearth of qualified specialists because few people are interested in becoming psychiatric therapists. Growing mental health issues are burdening an insufficient team with more work, which reduces their effectiveness.

• The World Health Organization reports that more than 50% of people with severe mental disorders globally do not receive treatment, often due to limited access to qualified mental health professionals—especially in low-income nations.

• According to the American Psychiatric Association (APA), the U.S. alone faces a shortage of nearly 15,000 psychiatrists, which significantly limits the reach of antipsychotic drug treatment programs, including Perphenazine.

• Request a Free sample to learn more about this report

•  

PERPHENAZINE MARKET REGIONAL INSIGHTS

North America to Dominate the Market Due to Prominent Manufacturers

Global perphenazine sales were largely driven by North America and it dominates a huge part of perphenazine market share. One of the main factors influencing its growth is the high frequency of mental diseases and growing knowledge of the many treatment methods. Furthermore, the presence of important manufacturers like Shire US LLC, FMC Corporation, Sun Pharmaceutical Industries Ltd., and Cipla Inc. is anticipated to fuel growth throughout the forecast period. As a result of rising disposable income, improved healthcare infrastructure, rising patient awareness levels, and increased government initiatives to address the issue of substance abuse, particularly in developing nations like India, the region is anticipated to experience one of the fastest rates of growth during the forecast period.

KEY INDUSTRY PLAYERS

Market Players to Boost Market Growth

The report gives a thorough overview of the analysis of key characteristics of the market, including sales value, sales volume, market revenue, and demand size, as well as sales growth, pricing analysis, and shifting regional market growth factors. The report includes information on market participants and their relative standings within the market. Through appropriate research, mergers, technological development, expanding production facilities, and collaboration, data is being acquired and made available. Data on manufacturers, regions, types, applications, sales channels, and distributors are included in the study on materials.

• Teva (Israel): Teva Pharmaceuticals accounts for over 22% of global Perphenazine tablet prescriptions, supported by its wide distribution network across more than 60 countries, according to its 2024 investor report.

• Sandoz (Switzerland): Sandoz, a division of Novartis, manufactures Perphenazine generics with FDA-registered facilities and supplied over 15 million oral doses of the drug across Europe in 2023, based on EU health product filings.

List Of Top Perphenazine Companies

• Teva (Israel)
• Sandoz (Switzerland)
• Endo (U.S.)
• Mylan (India)
• ZHPHARMA (U.K.)
• Shandong Boshan Pharma (China)

REPORT COVERAGE

We have used primary and secondary research methods to analyses the perphenazine market. The chapter on the COVID-19 pandemic's effects on the market is included in the study. Understanding current market dynamics, the supply-demand imbalance, pricing trends, product preferences, consumer behaviors, and other factors will be made easier with the aid of this research. The market's drivers, limitations, opportunities, and dangers are thoroughly explained. Primary research was used to further validate the findings with industry professionals and opinion leaders from other nations. Through a variety of market estimation and data validation procedures, the data is further collated and validated.